Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia

We evaluated patients with newly diagnosed ALL treated at the Cleveland Clinic during the years 1996 through 2005. Cox proportional hazards analysis was used to identify univariate and multivariate correlates of complete remission, overall survival and progression-free survival. On univariate analysis, significant prognostic factors included: age at diagnosis (per 10-year increase), poor risk cytogenetics, time to white blood count recovery, and time from induction chemotherapy (IC) to post-remission therapy (PRT). In patients age <60 years without poor risk cytogenetics, time from IC to PRT (per week increase) was a significant prognostic factor by multivariate analysis and was associated with a decreased progression-free survival [HR 1.27, CI (1.04–1.55), p = 0.019] and decreased overall survival [HR 1.34, CI (1.08–1.67), p = 0.009]. Delayed time from IC to PRT (≥6.6 weeks) was associated with a statistically worse progression-free and overall survival.

[1]  M. Tallman,et al.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.

[2]  Jiong Hu,et al.  NOTCH1 Mutations in T-Cell Acute Lymphoblastic Leukemia: Prognostic Significance and Implication in Multifactorial Leukemogenesis , 2006, Clinical Cancer Research.

[3]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[4]  T. Naoe,et al.  Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia , 2006, Cancer.

[5]  K. Faber,et al.  Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia , 2005, Clinical Cancer Research.

[6]  C. Bloomfield,et al.  Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802. , 2005 .

[7]  D. Scheinberg,et al.  A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL , 2005 .

[8]  Thomas Flohr,et al.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.

[9]  J. Cayuela,et al.  Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Michael N Dworzak,et al.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.

[11]  C. Bloomfield,et al.  Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. , 1999, Blood.

[12]  R. Larson,et al.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.

[13]  M. Andreeff,et al.  A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Ganser,et al.  Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. , 1988, Blood.

[15]  R. Dinsmore,et al.  Current status of treatment of acute leukemia in adults: an overview of the Memorial experience and review of literature. , 1986, Critical reviews in oncology/hematology.

[16]  M. Andreeff,et al.  Acute lymphoblastic leukemia in adults. , 1985, Seminars in oncology.